search results for 
Logo

Share key data

KEY DATA OF THE FRESENIUS SHARE


  2012 2011 2010 2009 2008
1 Xetra closing price on the Frankfurt Stock Exchange 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange (ordinary and preference shares until January 28, 2011) 3 Proposal 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA, adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs (€29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG. 5 Adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and Contingent Value Rights (CVR) 6 Before special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)
Number of shares 178,188,260 163,237,336 162,450,090 161,315,376 161,143,734
Stock exchange quotation1 in €          
High 96.38 75.62 67.59 43.76 60.87
Low 72.07 59.90 41.80 27.69 31.93
Year-end quotation 87.10 71.48 62.75 43.45 36.23
Market capitalization2 in million € 15,520 11,668 10,301 7,538 6,270
Total dividend distribution in million € 196.03 155.1 139.7 121.8 113.6
Dividend per share in € 1.103 0.95 0.86 0.75 0.70
Earnings per share in € 5.424 4.735 4.085 3.185 2.856

  2012 2011 2010 2009 2008
1 Xetra closing price on the Frankfurt Stock Exchange 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange (ordinary and preference shares until January 28, 2011) 3 Proposal 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA, adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs (€29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG. 5 Adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and Contingent Value Rights (CVR) 6 Before special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)
Number of shares 178,188,260 163,237,336 162,450,090 161,315,376 161,143,734
Stock exchange quotation1 in €          
High 96.38 75.62 67.59 43.76 60.87
Low 72.07 59.90 41.80 27.69 31.93
Year-end quotation 87.10 71.48 62.75 43.45 36.23
Market capitalization2 in million € 15,520 11,668 10,301 7,538 6,270
Total dividend distribution in million € 196.03 155.1 139.7 121.8 113.6
Dividend per share in € 1.103 0.95 0.86 0.75 0.70
Earnings per share in € 5.424 4.735 4.085 3.185 2.856

Continue reading:
Analysts recommendations

QUICKFINDER

History

External related links

Tools